CytImmune Sciences, Inc.

Researchers from Cytimmune Sciences presented new data at a cancer therapeutics conference in Boston, MA demonstrating the potential of their nanoparticle-based platform to supercharge synergistic immune system stimulators called cytokines. SUMMARY OF DATA PRESENTED Data focused on industry leading, first-in-class, multi-cytokine immunotherapies CYT-IFNg-TNFa (A dual cytokine immunotherapy nanomedicine) 100x increase in direct cancer cell killing potency vs native cytokines 30x increase in cytokine accumulation in tumor tissue Induction of a cancer specific immune response after treatment Other novel cytokine-based immunotherapies Introduction of nanomedicines including combinations of IL-12, IL-2, IL-15 & IL-1b 175x increase in potency of IL-12 presented on nanoparticles vs. native IL-12 CYT-6091 (high dose TNF alpha) Unpublished preclinical data showing CYT-6091 induces cytotoxic T-Cell tumor infiltration Phase 1 clinical safety data and preclinical mechanism of action data ROCKVILLE, Md., Aug. 23, 2022 /PRNewswire/ -- Researcher from Cytimmune Sciences, a clinical-stage biotechnology company, presented new data on the company's novel cancer nanomedicines at the Cytokine Drug Development Conference held in Boston, Massachusetts on July 26-28. David Oarr, Cytimmune's president, participated in the events opening panel to discuss the current clinical status and future anticipated progress in the use of cytokines in the treatment of cancer. Giulio Paciotti, PhD, Cytimmune's chief science officer, was a featured speaker at the event and presented data on the company's novel cytokine-based nanomedicines, which have been designed to make these promising immune stimulating molecules safer and more effective. Cytokines are immune system signaling molecules that have enormous clinical potential including the ability to destroy critical tumor support structures such as blood vessels, drive a multi-faceted anti-cancer immune response, and initiate targeted killing of cancer cells. David Oarr described the challenges historically associated with cytokine delivery. "Clinical use of this class of immune system molecules has been hampered by high levels of off-target toxicity, an inability to deliver multiple cytokines in combination, and very short half-lives. Cytimmune is focused on designing therapies that overcome these challenges." Dr. Paciotti presented a combination of preclinical and clinical data on the company's nanomedicine assets to demonstrate that Cytimmune's nanoparticle platform may provide a viable clinical solution to the toxicity and short half-life challenges associated with most cytokines. Additional data were presented to illustrate Cytimmune's unique approach to packaging combinations of high doses of multiple cytokines on a single nanoparticle. Dr. Paciotti explained the significance of this technology: "Combination delivery of cytokines is essential to maximizing the efficacy of these molecules against solid tumor cancers. We believe our data clearly show that using our nanoparticle platform to simultaneously deliver synergistic cytokines such as Interferon gamma and Tumer Necrosis Factor alpha, or Interleukins 2 and 12, can result in an increase in anti-cancer effect of more than 100-fold. Additionally, our preclinical data show that even individual cytokines delivered on our nanoparticle platform are vastly more potent than native cytokines delivered at the same concentration. I believe supercharged cytokine combinations have the potential to be a game-changer immunotherapy in the treatment of solid tumor cancers." ABOUT CYTIMMUNE Cytimmune is a phase 1b/2 ready oncology company developing multiple assets to treat solid tumor cancers. The company's lead asset, CYT-6091, is a novel cancer nanomedicine that destroys tumor blood vessels within hours of administration and recruits cytotoxic T-Cells into solid tumors. The U.S. National Cancer Institute (NCI) has signed a clinical trial agreement with Cytimmune to conduct phase 1b and multiple phase 2 clinical trials in which CYT-6091 will be combined with paclitaxel to treat orphan endocrine cancers of the thyroid and pancreas. BACKGROUND LINKS SAFE HARBOR STATEMENT This press release includes forward-looking statements that may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "can," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and Cytimmune cautions against placing undue reliance on such statements. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. Media Contact: David Oarr 202-725-0477 342947@email4pr.com

Dublin, June 15, 2021 (GLOBE NEWSWIRE) -- The "Global Nanomedicines Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. Nanotechnology involves the miniaturization of larger structures and chemicals at a nanometric scale for drug administration. The global nanomedicines market is projected to grow at a modest CAGR of 11.1% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the various innovations in nanotechnology for medicines along with the rise in the prevalence of various diseases such as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. Developments in nanorobotics along with government support are further expected to propel the growth of the market over the forecast period.The global nanomedicines market is segmented on the basis of indication type and application. Based on the indication type, the market is segmented as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. The other segment includes urological disease and ophthalmic diseases. The cardiovascular diseases segment is likely to hold a substantial share in the market over the forecast period. Based on the applications, the market is segmented as drug delivery, active implants, vaccines, diagnostic imaging, biomaterials, regenerative medicines, and other applications. The other segment includes tissue regeneration. The drug delivery segment is likely to hold a substantial share in the market over the forecast period.Based on the demographic viewpoint, the market is segmented as North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is projected to hold a significant market share over the forecast period owing to various R&D activities conducted by the key players. Further, 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others are some of the prominent players functioning in the global Nanomedicine market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.Market Segmentation:1. Global Nanomedicine Market Research and Analysis by Indication Type2. Global Nanomedicine Market Research and Analysis by ApplicationsThe Report covers: Key Topics Covered: 1. Report Summary2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion3. Competitive Landscape3.1. Competitive Dashboard3.2. Key Strategy Analysis3.3. Key Company Analysis3.3.1. 3M Co.3.3.1.1. Overview3.3.1.2. Financial Analysis3.3.1.3. SWOT Analysis3.3.1.4. Recent Developments3.3.2. Johnson & Johnson Services Inc.3.3.2.1. Overview3.3.2.2. Financial Analysis3.3.2.3. SWOT Analysis3.3.2.4. Recent Developments3.3.3. Merck & Co. Inc.3.3.3.1. Overview3.3.3.2. Financial Analysis3.3.3.3. SWOT Analysis3.3.3.4. Recent Developments3.3.4. Thermo Fisher Scientific Inc.3.3.4.1. Overview3.3.4.2. Financial Analysis3.3.4.3. SWOT Analysis3.3.4.4. Recent Developments3.3.5. Eli Lily & Co.3.3.5.1. Overview3.3.5.2. Financial Analysis3.3.5.3. SWOT Analysis3.3.5.4. Recent Developments4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities5. Market Segmentation5.1. Global Nanomedicine Market by Indication Type5.1.1. Cardiovascular Diseases5.1.2. Neurological Diseases5.1.3. Infectious Diseases5.1.4. Oncological Diseases5.1.5. Orthopedic Diseases5.1.6. Other Diseases (Urological Disease, Ophthalmic Diseases)5.2. Global Nanomedicine Market by Application5.2.1. Drug Delivery5.2.2. Active Implants5.2.3. Vaccines5.2.4. Diagnostic Imaging5.2.5. Biomaterials5.2.6. Regenerative Medicines5.2.7. Other Applications (Tissue Regeneration)6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe6.3. Asia-Pacific6.3.1. China6.3.2. India6.3.3. Japan6.3.4. ASEAN6.3.5. South Korea6.3.6. Rest of Asia-Pacific6.4. Rest of the World7. Company Profiles7.1. Affymetrix Inc.7.2. AstraZeneca Plc.7.3. Bristol-Myers Squibb Co.7.4. Celgene Corp.7.5. CytImmune Sciences Inc.7.6. Ferro Corp.7.7. GE Global Research7.8. Gilead Sciences Inc.7.9. Luminex Corp.7.10. Nanobiotix SA7.11. PerkinElmer Inc.7.12. Pfizer Inc.7.13. Sanofi SA7.14. Shimadzu Co. Ltd7.15. Smith & Nephew Plc7.16. St. Jude Medical Inc.7.17. Starpharma Holdings Ltd.7.18. Stryker Corp.7.19. Taiwan Liposome Co. Ltd.7.20. UCB SAFor more information about this report visit